A Clinical Study to Assess the Effect of a Dietary Supplement on Menstrual Cycle Symptoms
NCT ID: NCT07267728
Last Updated: 2025-12-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
40 participants
INTERVENTIONAL
2025-02-01
2025-07-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study to Evaluate the Efficacy of Elix's Cycle Balance and Its Impact on PMS and Menstrual Symptoms
NCT05145257
A Randomized Placebo-Controlled Study to Evaluate the Effects of a Gummy and Capsule Supplement on Symptoms of Premenstrual Syndrome
NCT06763809
A Single Group Study to Evaluate the Effects of a Supplement on Premenstrual Syndrome
NCT06124326
A Study to Assess the Effect of My Happy Flo on Alleviating Period Symptoms and Heavy Flows.
NCT06522672
A Single Group Study to Evaluate the Effects of a Topical Product on Cramps Associated With the Menstrual Cycle
NCT06939972
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
DITTO Cycle Supplement
Participants will take two capsules of the DITTO Cycle Supplement once daily, starting two days after menstrual bleeding ends, for the duration of three menstrual cycles.
DITTO Cycle Supplement
The capsules should be taken in the morning with the first meal and a glass of water.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
DITTO Cycle Supplement
The capsules should be taken in the morning with the first meal and a glass of water.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Aged 18-45
* In the last three menstrual cycles, has experienced three or more of the following symptoms associated with their menstrual cycle: Menstrual cramps, Bloating, Breast tenderness, Headaches, Fatigue, Muscle aches and/or joint pain, Cravings, Mood swings, Low mood, Feelings of anxiety, Irritability, Difficulty concentrating
* Generally healthy - does not live with any uncontrolled chronic disease
* Has a regular menstrual cycle length, between 23 and 35 days
* Tracks their menstrual cycle and can predict their period dates
* Anyone willing to comply with study requirements
* Anyone with no known allergies to the ingredients listed in the product
Exclusion Criteria
* Women who are pregnant, breastfeeding, or trying to conceive
* Anyone unwilling to follow the study protocol
* Anyone in perimenopause, menopause, or experiencing menopausal-type symptoms
* Anyone with planned surgery during the study period
* Anyone with a history of substance abuse
* Anyone diagnosed with high blood pressure, high cholesterol, heart disease, heart attack, stroke, irregular heartbeat (AFib), clogged arteries, poor circulation, heart failure, or other heart conditions
* Anyone diagnosed with a hormone or reproductive health-related cancer or benign condition
* Anyone diagnosed with a menstrual health condition such as endometriosis, PCOS, or adenomyosis
* Anyone diagnosed with diabetes or other endocrine-related condition
* Anyone currently participating or planning to participate in a research study
* Anyone who has started, changed, or stopped taking hormonal birth control in the last three months
* Has a planned insertion or replacement of an IUD in the next 12 weeks
18 Years
45 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Citruslabs
INDUSTRY
Muse Nutrition Ltd
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Citruslabs
Las Vegas, Nevada, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
20736
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.